Nectar Lifesci.

Which are the latest news on Nectar Lifesci.?

Why is Nectar Lifescience Ltd falling/rising?

As of 05-Sep, Nectar Lifescience Ltd's stock price is currently rising at 12.22, showing a short-term positive trend despite significant long-term declines of 37.33% year-to-date and 54.56% over three years. The recent increase may indicate temporary recovery, although delivery volume has decreased, suggesting lower investor participation.

As of 05-Sep, Nectar Lifescience Ltd's stock price is rising, currently at 12.22, with a change of 0.07 (0.58%) upward. This increase can be attributed to its performance today, where it outperformed the sector by 0.86%. Additionally, the stock's current price is higher than the 20-day, 50-day, and 100-day moving averages, indicating a positive short-term trend. <BR><BR>However, it is important to note that the stock has experienced significant declines over longer periods, with a year-to-date drop of 37.33% and a three-year decline of 54.56%. Despite these long-term challenges, the recent uptick in price suggests a temporary recovery or positive sentiment among investors, even as delivery volume has fallen by 39.63% compared to the five-day average, indicating a decrease in investor participation. Overall, while the stock is currently rising, it faces ongoing challenges reflected in its longer-term performance metrics.

Who are in the management team of Nectar Lifesci.?

The management team of Nectar Lifesci includes Sanjiv Goyal (Chairman & Managing Director), Ajay Swaroop, Meena Verma, Rupinder Tewari, Kuldip Kumar Bhasin, Indu Pal Kaur (all Independent Directors), Anubha (Company Secretary & Compliance Officer), and Puneet Sud (Director of Operations). They oversee the company's strategic direction and operations.

The management team of Nectar Lifesci includes the following individuals:<BR><BR>1. **Sanjiv Goyal** - Chairman & Managing Director<BR>2. **Ajay Swaroop** - Independent Director<BR>3. **Meena Verma** - Nominee<BR>4. **Rupinder Tewari** - Independent Director<BR>5. **Anubha** - Company Secretary & Compliance Officer<BR>6. **Kuldip Kumar Bhasin** - Independent Director<BR>7. **Indu Pal Kaur** - Independent Director<BR>8. **Puneet Sud** - Director (Operations)<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

What does Nectar Lifesci. do?

Nectar Lifescience Ltd is a pharmaceutical company focused on manufacturing high-quality products, particularly in the Cephalosporins segment. As of June 2026, it reported net sales of 0 Cr and a net loss of 15 Cr, with a market cap of INR 245 Cr.

Overview:<BR>Nectar Lifescience Ltd is an integrated pharmaceutical organization specializing in the manufacturing and delivery of high-quality pharmaceutical products, particularly in the Cephalosporins segment, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>History:<BR>Nectar Lifescience Ltd was incorporated on June 27, 1995, originally named 'Surya Medicare Limited'. The company changed its name to 'Nectar Lifescience Limited' on March 26, 2004. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -15 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 245 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.21 <BR>Return on Equity: -20.51% <BR>Price to Book: 0.42<BR><BR>Contact Details:<BR>Address: Village Saidpura, Tehsil Derabassi S A S Nagar Mohali Punjab : 140507 <BR>Phone: 91-1762-308000 <BR>Email: cs@neclife.com <BR>Website: http://www.neclife.com

Who are the peers of the Nectar Lifesci.?

Nectar Lifesci.'s peers include Zenotech Lab., Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Kerala Ayurveda, Natural Capsules, and Sanjiv.Parant. Its 1-year return is -12.78%, better than Kerala Ayurveda's -63.87% but worse than Astonea Labs' 57.61%.

Peers: The peers of Nectar Lifesci. are Zenotech Lab., Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Kerala Ayurveda, Natural Capsules, Sanjiv.Parant., Coral Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Coral Labs, while Average management risk is found at Zenotech Lab., Astonea Labs, Everest Organics, Lyka Labs, and Nectar Lifesci. Below Average management risk is noted at Aarey Drugs, Kerala Ayurveda, Natural Capsules, and Coral Labs. Growth is rated as Excellent at Accretion Pha., Good at Astonea Labs and Sanjiv.Parant., while Average growth is seen at Zenotech Lab., Lyka Labs, and Nectar Lifesci. Below Average growth is present at Everest Organics, Aarey Drugs, Kerala Ayurveda, Natural Capsules, and Coral Labs. Capital Structure is Excellent at Zenotech Lab. and Coral Labs, Below Average at Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Kerala Ayurveda, Natural Capsules, and Nectar Lifesci., and Good at Accretion Pha.<BR><BR>Return Snapshot: Astonea Labs has the highest 1-year return at 57.61%, while Kerala Ayurveda has the lowest at -63.87%. Nectar Lifesci.'s 1-year return of -12.78% is better than Kerala Ayurveda's but worse than Astonea Labs'. Additionally, Everest Organics, Kerala Ayurveda, and Sanjiv.Parant. have negative six-month returns.

How big is Nectar Lifesci.?

As of 31st August, Nectar Lifescience Ltd has a market capitalization of 245.00 Cr and reported Net Sales of 2.44 Cr, with a Net Profit loss of 245.06 Cr over the latest four quarters. The balance sheet for March 2026 shows Shareholder's Funds of 582.29 Cr and Total Assets of 397.13 Cr.

As of 31st August, Nectar Lifescience Ltd has a market capitalization of 245.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2.44 Cr. However, it faced a loss of 245.06 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 582.29 Cr and Total Assets of 397.13 Cr.

Should I buy, sell or hold Nectar Lifescience Ltd?

When is the next results date for Nectar Lifescience Ltd?

The next results date for Nectar Lifescience Ltd is 14 August 2026.

The next results date for Nectar Lifescience Ltd is scheduled for 14 August 2026.

Are Nectar Lifescience Ltd latest results good or bad?

Nectar Lifescience Ltd's latest results are concerning, showing a consolidated net loss of ₹67.92 crores in Q4 FY26, a significant decline from the previous quarter, with revenues at just ₹1.29 crores. The company's financial health is deteriorating, reflected in a 54.28% drop in stock value over the past year and a low Mojo Score of 9 out of 100, indicating a "STRONG SELL" recommendation.

Nectar Lifescience Ltd's latest results are quite concerning. In Q4 FY26, the company reported a consolidated net loss of ₹67.92 crores, which is a staggering 575.96% decline compared to the previous quarter. The standalone net loss also worsened significantly, going from a profit of ₹0.30 crores in Q3 FY26 to a loss of ₹37.21 crores in Q4 FY26.<BR><BR>Revenue for the quarter was only ₹1.29 crores, a minimal recovery from ₹0.00 crores in the previous quarter, but still far below the ₹5.24 crores generated in Q2 FY26. This erratic revenue pattern indicates severe operational challenges, and the company's operating loss before depreciation, interest, and taxes hit a record low of ₹57.24 crores.<BR><BR>The overall financial health of the company appears to be deteriorating, with a market capitalization of just ₹241 crores and the stock down 54.28% over the past year. The company's Mojo Score stands at a dismal 9 out of 100, categorizing it firmly in "STRONG SELL" territory. <BR><BR>In summary, the latest results reflect a company in crisis, struggling with operational collapse, persistent losses, and a lack of clear pathways to recovery.

How has been the historical performance of Nectar Lifesci.?

Nectar Lifesci has experienced significant financial declines, with net sales dropping from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025, and operating profit turning negative with a loss of 26.46 Cr in March 2025. Key metrics, including profit before tax and profit after tax, have also deteriorated, reflecting an overall downward trend in performance.

Answer:<BR>The historical performance of Nectar Lifesci shows significant fluctuations in financial metrics over the years.<BR><BR>Breakdown:<BR>Nectar Lifesci's net sales peaked at 2,782.94 Cr in March 2019 but have since declined, reaching 1,673.07 Cr in March 2025. The total operating income followed a similar trend, decreasing from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025. The company experienced a notable drop in operating profit, with a loss of 26.46 Cr in March 2025 compared to a profit of 166.14 Cr in March 2024. This decline in profitability is reflected in the profit before tax, which fell to -161.53 Cr in March 2025 from a profit of 18.27 Cr in the previous year. The profit after tax also turned negative, resulting in a loss of 113.68 Cr in March 2025, contrasting with a small profit of 4.99 Cr in March 2024. The company's total liabilities decreased from 2,183.58 Cr in March 2024 to 1,992.18 Cr in March 2025, while total assets also declined from 2,183.58 Cr to 1,992.18 Cr in the same period. Cash flow from operating activities was 169 Cr in March 2025, down from 224 Cr in March 2024, indicating a decrease in operational efficiency. Overall, Nectar Lifesci's financial performance has shown a downward trend in key metrics over the past several years.

Who are the top shareholders of the Nectar Lifesci.?

The top shareholders of Nectar Lifesci include individual investors holding approximately 44.12%, with Sanjiv Goyal as the largest promoter at 24.9%. Notably, 99.6% of promoter holdings are pledged, and the highest public shareholder is Jaideep Sampat at 2%.

The top shareholders of Nectar Lifesci include a mix of individual and institutional investors. The majority of the shares are held by non-institutional shareholders, with individual investors holding approximately 44.12% of the company. The promoter with the highest holding is Sanjiv Goyal, who owns 24.9% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding about 0.81% of the company. The highest public shareholder is Jaideep Sampat, with a holding of 2%. It's worth noting that a significant portion of the promoter holdings, about 99.5995%, is pledged.

Is Nectar Lifesci. overvalued or undervalued?

As of July 8, 2025, Nectar Lifesciences is considered overvalued and risky due to its negative PE ratio of -3.66 and poor financial metrics compared to peers, alongside a significant year-to-date stock underperformance of -52.49% against the Sensex's 7.13% return.

As of 8 July 2025, Nectar Lifesciences has moved from an attractive to a risky valuation grade. The company appears to be overvalued given its negative PE ratio of -3.66, an EV to EBIT of -11.55, and an EV to EBITDA of -38.76. These figures indicate significant financial distress compared to its peers, such as Sun Pharma, which has a PE ratio of 35.1 and an EV to EBITDA of 24.8, and Cipla, with a PE of 22.8 and an EV to EBITDA of 15.79.<BR><BR>The stark contrast in valuation metrics highlights Nectar Lifesciences' precarious position within the pharmaceuticals and biotechnology industry. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -52.49% compared to the Sensex's 7.13%. This further reinforces the conclusion that Nectar Lifesciences is overvalued in its current state.

Is Nectar Lifesci. technically bullish or bearish?

As of July 7, 2025, the market trend is mildly bearish, influenced by bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and KST, indicating a cautious outlook.

As of 7 July 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating bearishness and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on the weekly timeframe is mildly bullish, which provides some counterbalance, but the overall indicators suggest a lack of strong bullish momentum. The KST is mildly bullish on the weekly but remains bearish on the monthly, further indicating mixed signals. The lack of clear trends in Dow Theory and the OBV being mildly bearish on the monthly reinforce the cautious outlook.

Has Nectar Lifesci. declared dividend?

Nectar Lifescience Ltd has declared a 5% dividend, amounting to 0.05 per share, with an ex-date of September 11, 2020. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different periods.

Nectar Lifescience Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.05<BR>- Ex-date: 11 Sep 20<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -26.58%, the dividend return was 0%, resulting in a total return of -26.58%.<BR><BR>For the 1-year period, the price return was -20.92%, the dividend return was 0%, leading to a total return of -20.92%.<BR><BR>Over the 2-year period, the price return was 40.37%, the dividend return was 0%, which resulted in a total return of 40.37%.<BR><BR>In the 3-year period, the price return was -3.98%, the dividend return was 0%, culminating in a total return of -3.98%.<BR><BR>During the 4-year period, the price return was -27.77%, the dividend return was 0%, resulting in a total return of -27.77%.<BR><BR>For the 5-year period, the price return was 67.52%, the dividend return was 0.21%, leading to a total return of 67.73%.<BR><BR>Overall, while Nectar Lifescience Ltd declared a dividend, the dividend yield remains at 0%. The total returns show significant variability, with a notable positive return over the 2-year and 5-year periods, contrasting with negative returns in shorter time frames.